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Renal Aplasia in Humans Is Associated with RET Mutations
Michael A. Skinner,1,* Shawn D. Safford,2 Justin G. Reeves,3 Margaret E. Jackson,4
and Alex J. Freemerman4
In animal models, kidney formation is known to be controlled by the proteins RET, GDNF, and GFRA1; however, no human studies to
date have shown an association between abnormal kidney development and mutation of these genes. We hypothesized that stillborn
fetuses with congenital renal agenesis or severe dysplasia would possess mutations in RET, GDNF, or GFRA1. We assayed for mutations in
these genes in 33 stillborn fetuses that had bilateral or unilateral renal agenesis (29 subjects) or severe congenital renal dysplasia (4 sub-
jects). Mutations in RETwere found in 7 of 19 fetuses with bilateral renal agenesis (37%) and 2 of 10 fetuses (20%) with unilateral agen-
esis. In two fetuses, there were two different RET mutations found, and a total of ten different sequence variations were identiﬁed. We
also investigated whether these mutations affected RETactivation; in each case, RET phosphorylation was either absent or constitutively
activated. AGNDFmutationwas identiﬁed in only one fetus with unilateral agenesis; this subject also had two RETmutations. NoGFRA1
mutations were seen in any fetuses. These data suggest that in humans, mutations in RET and GDNF may contribute signiﬁcantly to
abnormal kidney development.Introduction
Congenital renal agenesis or dysgenesis is rare in humans,
occurring at a frequency of 1/3000–1/5000 births.1 Several
lines of evidence suggest a genetic contribution to the de-
velopment of these anomalies. For example, the incidence
of renal agenesis is increased in fetuses who have ﬁrst
degree relatives with congenital renal anomalies.2 More-
over, renal anomalies are associated with some autosomal
recessive and dominantly inherited disorders including
Meckel-Gruber (MIM #249000), Townes-Brocks (MIM
#107480), and Ivemark (MIM 208530) syndromes. Finally,
animal genetic models have implicatedmany genes impor-
tant for renal development.3
More than 40 genes have been shown to be involved in
murine kidney development.4 Major developmentally im-
portant proteins include Ret (MIM #164761), Gdnf (MIM
*600837), Gfra1 (MIM *601496), Pax2 (MIM *167409),
and Wt1 (MIM *607102). In mice, renal agenesis is com-
monly found in animals lacking the genes for the tyrosine
kinase receptor Ret, its coreceptor Gfra1, or the Gfra1
ligand Gdnf.5–7 However, in humans, the genes responsi-
ble for kidney development have remained elusive.3 Anec-
dotal reports in humans noting the ﬁnding of renal dys-
plasia in multiple endocrine neoplasia (MEN) 2A (MIM
#171400) kindreds with RET mutations have suggested
that genes from the RET axis may be important in human
kidney development.8,9 However, the RET, GDNF, and
GFRA1 genes have not been carefully studied in humans
with severe renal anomalies, perhaps owing to the fre-
quent stillbirth of such infants. We hypothesize that muta-
tions in RET, GDNF, and GFRA1 might occur with high
frequency in stillborn fetuses having renal agenesis or
dysplasia.344 The American Journal of Human Genetics 82, 344–351, FebruaryMaterial and Methods
Identiﬁcation of RET and GDNF Mutations
Parafﬁn-embedded tissue samples were collected from 33 autop-
sied stillborn fetuses with bilateral renal agenesis (n ¼ 19), unilat-
eral renal agenesis (n ¼ 10), and severe renal dysgenesis including
two patients withMeckel-Gruber syndrome (n¼ 4). The study was
approved by the Institutional Review Board, and in accordance
with our IRB, consent was waived because the parafﬁn-embedded
samples were archival and were studied in a completely anony-
mous fashion. Based on their autopsy ﬁndings including biopsy
of the colon, none of the patients had Hirschsprung disease
(MIM #142623). Moreover, there was no evidence of multiple
endocrine neoplasia (MEN) 2A or 2B (MIM #162300) or familial
medullary thyroid carcinoma (FMTC) (MIM #155240), but these
conditions generally present with clinical ﬁndings later in child-
hood; they may have been present in our subjects and were not
detected at standard autopsy in these infants.
We extracted DNA from the parafﬁn-embedded liver and spleen
tissue through xylene deparafﬁnization of multiple 10-micron
tissue sections followed by protein digestion and ethanol precipi-
tation of DNA. This DNAwas then used as the template to amplify
by PCR each exon in the RET, GDNF, and GFRA1 genes, and these
PCR products were screened for mutations by conformation sen-
sitive gel electrophoresis (CSGE).10,11 To generate exonic DNA
segments for CSGE, oligonucleotides were designed to ﬂank
exonic regions 200–400 basepairs in length bymeans of published
sequence from the Human Genome Database or other published
studies.10,11 PCR was performed with a touchdown protocol
(94.0C/2:00, 20 3 [94C/:30, 63.5C/:45*, 72.0C/1:00], 25 3
[94.0C/:30, 53.5C/:45, 72.0C/1:00] *annealing temperature
decreases 0.5C each cycle) and Platinum Pfx Polymerase with
10 ml reactions (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s speciﬁcations. Abnormally migrating or ambiguous
exons found by CSGE were then ampliﬁed twice independently
by PCR and sequenced in both directions. Normal human DNA
served as the control for both PCR and CSGE.1Division of Pediatric Surgery, Children’s Medical Center of Dallas and University of Texas Southwestern Medical School, Dallas, TX 75235, USA; 2Pediatric
General and Thoracic Surgery, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; 3Department of Medicine, 4Division of Pediatric Surgery,
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Normal and Mutant RET Expression
Plasmid Constructs
Expression plasmids containing the identiﬁed RET mutations
were created by site-directed PCR mutagenesis with wild-type
RET51 (1114 amino acids, RET51) as the template. The upstream
RET primer (gatctctagagccgccaccatggcgaaggcgacgtccggt) con-
tained an XbaI restriction site followed by a consensus Kozak se-
quence. The downstream primer (gatgcggccgcttaactatcaaacgtgtcc)
contained a NotI site for directional cloning. The resultant prod-
ucts were then cut and directionally ligated (XbaI-NotI) into the
mammalian expression vector, pCI-Neo (Clontech, Mountain
View, CA). The parental human neuroblastoma cell line, SK-N-
MC, was utilized to establish cell lines expressing normal RET51
and each mutant (cDNA)RET construct, as well as an empty vec-
tor control. Cells were transfected with the DNA constructs with
a cationic lipid and protocol from Bio-Rad (siLentFect) (Bio-Rad
Laboratories, Hercules, CA) and then selected in 800 mg/ml
G418 (Invitrogen) until the mock-transfected cells were all
dead. Then, entire transfected cell populations were used in sub-
sequent experiments. Transfectant cells were maintained in
400 mg/ml G418.
Chemicals
GDNF (R&D Systems, Inc., Minneapolis, MN) was reconstituted to
10 mg/ml in sterile PBS with 0.1% bovine serum albumin (BSA) and
stored at 70C under light-free conditions.
Cell Culture
All cultures were maintained under a fully humidiﬁed atmosphere
of 95% air and 5% CO2 at 37
C. Cells were grown in minimal
essential media (MEM) supplemented with 10% FBS, 13 nones-
sential amino acids, and penicillin/streptomycin antibiotic mix
(Sigma Chemical Co., St. Louis, MO). For experimental incuba-
tions, cells in log-phase growth were plated at a density of 1 3
105 cells/ml and allowed to attach overnight. Each cell line was
then treated with 100 ng/ml GDNF for 3 hr in serum-free MEM
media. Experimental incubations were terminated by collecting
cells, pelleting at 500 3 g for 5 min, and washing with 13 phos-
phate-buffered saline (PBS) and directly lysing cells in 13 Laemmli
(1% SDS, 10% glycerol, 100 mM dithiothreitol, 50 mM Tris [pH
6.8]) for western blots.Assays for RET51 Expression and Phosphorylation
To perform western blots, cell lysates were brieﬂy sonicated and
centrifuged at 12,800 3 g for 5 min. All samples were boiled for
5 min and equal amounts of protein (40 mg) were separated by
SDS-PAGE (4%–20% gradient) and electroblotted to 0.45 mMnitro-
cellulose membranes. Blots were stained with amido black (0.5%
[w/v] in 5% acetic acid) and destained with water to conﬁrm trans-
fer and equal loading and then blocked in 13 Tris-buffered saline
(0.8%NaCl, 2.7 mMKCl, 25 mM Tris [pH 7.4]) with 0.05% Tween-
20 (TBS-T) and 1% milk/1% BSA for 1 hr at 22C. The blots were
incubated in fresh blocking solution and probed for 1 hr with
a 1:1000 dilution of either anti-RET51 (C-20), anti-phospho-RET
(Tyr 1062-R), or anti-GFRA1 (H70) (Santa Cruz Biotechnology,
SantaCruz,CA)primary antibody. Theblotswerewashed335min
inTBS-Tand then incubatedwith a1:10,000dilutionofperoxidase-
conjugated secondary antibody (Santa Cruz Biotechnology) in
TBS-T for 1 hr at 22C. Blots were again washed 3 3 5 min in TBS-
T and then developed by enhanced chemiluminesence (Pierce,
Rockford, IL). Individual blots were stripped for 30 min with Re-
store (Pierce) and reprobedwith primary and secondary antibodies
as described above.The AmeResults
Mutation Analysis
We studied the DNA from 33 stillborn human fetuses with
renal aplasia or severe dysplasia to determine the inci-
dence of mutation in RET, GDNF, and GFRA1. To screen
for genetic mutations, ampliﬁed DNA from transcribed
regions of RET (22 exons), GDNF (3 exons), and GFRA1
(18 exons) were subjected to conformation sensitive gel
electrophoresis (CSGE).10,11 Abnormally migrating or am-
biguous exons identiﬁed by CSGE were subsequently
sequenced. In addition, to control for the possibility of
PCR-induced errors during ampliﬁcation, each suspect
exon was ampliﬁed twice independently and sequenced
in both directions to conﬁrm and identify the presence
of mutations. Normal human DNA served as the control
for PCR and CSGE. Human RET mutations were found in
37% of fetuses with bilateral renal agenesis and in 20%
of fetuses with unilateral renal agenesis (Figure 1). We did
not identify any RET mutations in fetuses with renal dys-
plasia or in normal control DNA. To assess the statistical
signiﬁcance of our ﬁndings, we have performed a Bayesian
analysis (Appendix A); this analysis demonstrates the
approximate likelihood of ﬁnding such misfunctioning
RET mutations in the general population to be very low
(0.00028 ¼ P(q)). In fetuses with bilateral agenesis, muta-
tions occurred throughout the RET gene and were about
evenly divided between the extracellular and intracellular
regions of the molecule (Figure 2). Four of the mutations
occurred in exon 6. Likewise, in the fetuses with unilateral
renal agenesis, mutations occurred with equal frequency in
both in the extracellular domain and in the intracellular
carboxy-terminal tail of RET (Figure 2). Lastly, one muta-
tion created a severe truncation (KP26). It should be noted
that in this study, we assayed formutations only in the RET
coding region, and mutations in noncoding regions of the
gene may have been present but undetected.
Mutations in GDNF were found in only one fetus with
unilateral renal agenesis (Figure 1). Fetuses with renal dys-
plasia had no identiﬁed mutations in GDNF. Of note, the
only sample with a GDNF mutation (KP25) also had two
mutations in RET. No mutations in GFRA1 were found in
any of our samples.Biochemical Analysis
We performed additional biochemical studies to determine
whether the identiﬁed RETmutations signiﬁcantly altered
RET activation in a cell-culture system. We created (cDNA)
RET constructs possessing the identiﬁed mutations as well
as normal (cDNA)RET51. We chose to use RET51 as the
cDNA template because the KP29 mutation is located
with the alternatively spliced carboxy-tail of RET51. We
evaluated RET51 phosphorylation in a cell-based assay by
transfecting the cDNA constructs into SK-N-MC cells.
These cells endogenously express GFRA1, and when solu-
ble GDNF is added to the media, a RET signaling complexrican Journal of Human Genetics 82, 344–351, February 2008 345
can be created, leading to RET phosphorylation. RET51-
expressing SK-N-MC cells (normal and mutants) were in-
cubated for 3 hr in either serum-free media (GDNF)
or media supplemented with 100 ng/ml soluble GDNF
(þGDNF). Western blots of the resulting cell lysates
(Figure 3) showed appropriate levels of expression of nor-
mal and each mutant RET. Interestingly, we found that
RETmutants KP7, KP16, KP17, and KP18 are constitutively
phosphorylated at tyrosine 1062, while KP14, KP19, KP25,
and KP29 are inactivated (not activated by GDNF as is
normal RET51). Additionally, the constitutively activated
mutants seem to be further activated by the addition of
soluble GDNF. Lastly, RET normally presents as a doublet
of 150 kDa and 170 kDa on western blots, with the larger
form representing the RET on the cell surface and the
smaller form representing a preprocessed intracellular
form.12,13 Although constitutively activated, both KP7 and
KP18 seem to express only the 150 kDa form of RET51
instead of the doublet usually observed.Discussion
Mutations in the RET proto-oncogene are responsible for
several diseases in humans. Initially, translocations in the
gene were found to be associated with papillary thyroid
cancer (MIM #188550);14 the frequency of this genetic
ﬁnding is especially high in thyroid cancer resulting346 The American Journal of Human Genetics 82, 344–351, February 2008Figure 1. RET and GDNF Mutations in
Fetuses with Bilateral or Unilateral
Renal Agenesis
Eight RET mutations were seen in 7/19 fe-
tuses (37%) with bilateral renal agenesis
(BA), and three RETmutations were discov-
ered in 2/10 fetuses (20%) with unilateral
renal agenesis (UA). One GDNF mutation
occurred in 1/10 fetuses (10%) with uni-
lateral renal agenesis.
from radiation exposure.15,16 Subse-
quently, it was discovered that certain
inherited mutations in RET are re-
sponsible for the multiple endocrine
neoplasia (MEN) 2A and 2B syn-
dromes, as well as the familial medul-
lary thyroid carcinoma (FMTC).17–21
In these RET-related cancers and neo-
plastic syndromes, there is constitu-
tive activation of the tyrosine kinase
domain, with increased downstream
signaling ultimately resulting in cel-
lular transformation and malig-
nancy.22,23 Conversely, Hirschprung
disease is a nonneoplastic disease as-
sociated with RET mutations that re-
duce RET tyrosine kinase activity,probably resulting in an embryonic microenvironment
that does not allow the normal development of enteric
ganglion cells in the affected bowel.24–28
We have shown that RET is frequently mutated in
humans with renal agenesis. This ﬁnding is consistent
with other experimental evidence supporting the impor-
tance of RET in renal development. For example, RET is
normally expressed in the Wolfﬁan duct of the developing
kidney in humans and mice,29,30 and mice lacking Ret
exhibit severe renal dysplasia or agenesis as a result of
defective ureteric bud outgrowth.29,30 Moreover, there are
reports describing the occurrence of familial unilateral
renal aplasia and FMTC8,9 and the rare coincidence of renal
aplasia and Hirschsprung disease.31,32 Taken together,
these ﬁndings suggest that congenital renal aplasia joins
Hirschsprung disease as another congenital human condi-
tion resulting from RETmutations that prevent or impede
the embryonic development of RET-dependant structures.
In this study, we deﬁned RETactivation as the phosphor-
ylation of RET at residue Y1062, because phosphorylation
of this tyrosine, in particular, has been shown to be critical
in kidney development.33 We detected four inactivating
RET mutations (KP14, KP19, KP25, KP29), four activating
RET mutations (KP7, KP16, KP17, KP18), and one RET
truncation (KP26). Four of these RET mutations have
been previously noted in humans. The mutations found
in samples KP14 and KP7 are associated with Hirschsprung
disease,34,35 and the mutations from samples KP16 and
KP17 are associated with sporadic medullary thyroid carci-
noma (MTC).36 Moreover, the M918T mutation in sample
KP17 causes the MEN2B syndrome, in addition to occur-
ring in sporadic MTC.
As depicted in Figure 2, inactivating RET mutations
occurred in both the extracellular and the intracellular
regions of RET. There are several mechanisms through
which these particular mutations may abrogate RET activ-
ity.28 For example, mutations in the intracellular carboxy-
terminal tail of RET, such as the ones we found in KP25 and
KP29, have been shown to impair SHC binding to RET
resulting in a RET-mediated signal defect.37,38 Alterna-
tively, mutations in the extracellular region have been
shown to impair proteinmaturation as well as protein-pro-
tein interactions between RET and its coreceptors.39–41 In
any case, the association of inactivating RET mutations
with renal aplasia in humans is certainly consistent with
the presence of severe renal anomalies inmice lacking Ret.5
What is perhaps surprising is that we also found renal
aplasia in individuals possessing activating RETmutations.
One of the four suchmutations was located in the extracel-
lular region (KP18) and three were in the intracellular
region (KP7, KP16, KP17). Other investigators have clearly
shown that activating mutations in RET can be associated
with both gain-of-function and loss-of-function pheno-
types.42 This phenomenonwas recently reported in a trans-
genic murine model in which animals were created
possessing Ret with the C620R mutation.43 This mutation
is generally transforming, and in humans has been associ-
ated with FMTC, MEN 2A, and in a minority of cases,
Hirschsprung disease. Mice with the homozygous C620R
Ret mutation demonstrated the absence of enteric ganglia
and kidneys, whereas the heterozygote transgenic animals
exhibited no such developmental abnormalities, but
developed premalignant tumors of the thyroid and adrenal
glands.44 We postulate that despite the presence of a con-
stitutively activated RET, there is a RET signaling defect
to cause a loss-of-function phenotype. Supporting this
hypothesis are reports in humans describing the occur-
rence of familial unilateral renal aplasia and FMTC8,9 and
the rare coincidence of renal aplasia and Hirschsprung
disease.31,32
Figure 2. Schematic Illustration of the Identified Mutations
in RET54 and GDNF in Stillborn Fetuses with Either Bilateral
Renal Agenesis or Unilateral Agenesis
Triangles signify the location and type of mutations. RET: S, signal-
ing domain; CLD, cadherin-like domain; CYS, cysteine-rich region;
TM, transmembrane region; TK, tyrosine kinase domain. GDNF: S,
signaling domain; CS, cleavage site.The AmeThere are several possible mechanisms by which an acti-
vating RET mutation results in a loss-of-function pheno-
type. First, asnotedabove, twoof themutationswedetected
(KP16 andKP17) are known to be associatedwithMTC, and
the cosegregation of Hirschsprung disease with MEN 2 has
been previously noted; it is likely that in our samples, renal
aplasia occurs through mechanism analogous to the agan-
glionosis in MEN 2 patients.42,45 In one recent report, it
was noted that in tissue culture, the Ret C620R mutation
has the ability to promote cellular proliferation, but impairs
the GDNF effects of Ret on cell migration, differentiation,
and survival.46 This duality in function may help explain
the ability of mutant RET to induce both the gain-of-func-
tion and loss-of-function phenotypes.
In our in vitro expression experiments, neither KP7 nor
KP18 exhibited the 170 kDa form of the protein on a
western blot that represents the mature cell surface
receptor. Indeed, others have reported that certain RET
mutations associated with Hirschsprung disease result
in the expression of only the immature, 150 kDa RET
Figure 3. Western Blots of Normal and Mutant RET51
Expressed in SK-N-MC Neuroblastoma Cells5 GDNF
Blots were sequentially probed for phospho-RET51 (Y1062) (pRET),
total RET51 (RET), and GFRA1.
Top gels: cell lysates with no GDNF added to the media. KP7, KP16,
KP17, and KP18 are constitutively phosphorylated.
Bottom gels: cell lysates treated with GDNF. Normal RET51 is
phosphorylated and KP7, KP16, KP17, and KP18 seem further phos-
phorylated. The RET mutations in KP14, KP19, KP25, and KP29
appear to inactivate RET51 (prevent autophosphorylation in
response to GDNF).rican Journal of Human Genetics 82, 344–351, February 2008 347
protein,39,40 and that this RET protein is localized to the
rough endoplasmic reticulum and Golgi.40 Through
a mechanism that prevents maturation and migration of
the RET molecule to the cell surface,40,47 such mutations
could disrupt ureteric branching of the kidney that is
dependent on RET signaling.5 Thus, each of the RETmuta-
tions detected in this study either inactivates RET or has
the potential to reduce overall RET signaling to account
for our phenotypic ﬁndings.
Hirschprung disease is a nonneoplastic disease associ-
ated with RET mutations that reduce RET tyrosine kinase
activity, probably resulting in an embryonicmicroenviron-
ment that does not allow the normal development of
enteric ganglion cells in the affected bowel.24–28 Thus, it
might be expected that the RETmutations leading to renal
aplasia in our subjects should also cause intestinal agan-
glionosis or Hirschsprung disease. However, it is likely
that RET is only one of a number of different genes co-
operating to support the embryonic development of kid-
neys and enteric ganglia. Indeed, segregation analysis has
suggested that three genetic loci are involved with familial
Hirschprung disease.48 Moreover, a polygenic process is
further supported by the incomplete penetrance of familial
Hirschsprung disease related to RET mutations.24,25 The
ﬁnding in the current study that RET mutations can
induce either unilateral or bilateral renal agenesis also
supports the notion that other genes may be important.
Finally, that RET-related renal agenesis and aganglionosis
are not strictly linked is further supported by a recent study
demonstrating that the transgenic introduction of a
mutated human RET gene into the Ret null murine back-
ground induced the development of nearly normal kid-
neys, but not enteric ganglia.49
Our study suggests that abnormal renal development is
rarely related to mutations in GDNF. This is consistent
with the extreme rarity of reported GDNF mutations,
which have been found in only a handful of patients
with Hirschsprung disease.50–52 It may be that such muta-
tions are not usually pathologic, or that in many cases
GDNF mutations cause early fetal demise. Indeed, in one
animal model, mutations in GDNF were found to be insuf-
ﬁcient to cause Hirschsprung disease.51 Interestingly, the
fetus in our study with a GDNF mutation also had two
RET mutations. The association of mutations in both RET
and GDNF has also been reported in Hirschsprung disease,
suggesting that RET and GDNF mutations may act in con-
cert to cause the intestinal aganglionosis, as well as the
renal anomalies seen in our study.50 This synergistic het-
erozygosity phenomenon has recently been described, in
which there is cooperation between two mutated genes
in a common pathway to induce a disease phenotype,53
and we speculate that the interaction between GDNF and
RET behaves similarly in renal development, requiring in
some cases both molecular events to occur before there is
renal aplasia.
In conclusion, this is the ﬁrst report to our knowledge
describing the association of RET mutations with renal348 The American Journal of Human Genetics 82, 344–351, Februaryagenesis in humans. It is possible that the lack of previous
reports is due to the devastating nature of renal agenesis,
causing most fetuses to die in utero. The high rate of RET
mutation in fetuses with renal agenesis suggests that
heterozygous mutations in RET may be responsible for
a signiﬁcant fraction of humans with abnormal kidney
development. Furthermore, the low mutation rate for
GDNF suggests a minor role for this gene in renal agenesis
or dysplasia. These data have signiﬁcant relevance to the
genetic communities in that it provides evidence for a pos-
sible mechanism of abnormal kidney development in
humans. Our ﬁndings suggest that congenital renal aplasia
joins Hirschsprung disease as another congenital human
condition resulting from RET mutations that prevent or
impede the embryonic development of RET-dependant
structures. Moreover, these data may support genetic
screening for RET mutations in individuals who have
had children born with abnormal kidneys or have miscar-
ried a child with abnormal kidneys.Appendix A
Statistical Analysis
We used a Bayesian analysis to approximate the expected
likelihood of misfunctioning RETmutations in the general
population, to determine the statistical signiﬁcance of our
genetic ﬁndings.
Let:
PðqÞ ¼ probability of a person in the general
population possessing a RET mutation
causing protein misfunction
PðYÞ ¼ probability of renal aplasia in the general
population ð¼ 1=3000Þ
and restating Bayes theorem:
Pðq jYÞ ¼ Pðq and YÞ=PðYÞ: (A1)
More commonly written:
Pðq jYÞ ¼ PðY j qÞ3PðqÞ=PðYÞ: (A2)
The left side of this equation, which is the probability of
ﬁnding a misfunctioning RET gene in patients with renal
aplasia, was found in our experiements to be approxi-
mately 0.31. In particular, we found such mutations in
9 of 29 subjects. By evaluating the binomial probability
distribution, the 95% conﬁdence interval for this experi-
mental ﬁnding in our population sample is consistent
with an actual population probability as low as 21%.
That is, the actual probability of RET misfunction in the
population of newborns with renal aplasia could be this
low and still be consistent with our ﬁnding of 9 cases in
29 subjects.
It remains to be shown that the probability of such
mutations in the general population, P(q), is signiﬁcantly2008
less than our (most conservative) experimental ﬁnding of
21% in subjects having renal aplasia.
Rearranging equation (A2) above,
Pðq jYÞ3PðYÞ=PðY j qÞ ¼ PðqÞ: (A3)
The term in the denominator of this equation, the prob-
ability that a subject with a RETmisfunction mutation will
exhibit renal aplasia, is simply the penetrance of such
mutations, and the valuemust be assumed. The penetrance
of RET mutations in Hirschsprung disease has been de-
termined to be 51% in females and 72% in males; for
the sake of conservatism in the current analysis, we will
assume the penetrance, P(Yjq), is only 25%.
Substituting the most conservative values into equation
(A3),
ð0:21Þð1=3000Þ=ð0:25Þ ¼ 0:00028 ¼ PðqÞ: (A4)
In conclusion, under our assumptions, we estimate that
the incidence of RET mutations causing abnormal protein
activation in the general population is approximately
1:3800, which varies signiﬁcantly from our ﬁnding of
such mutations in 9/29 subjects with renal aplasia.Acknowledgments
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